FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154834417> ?p ?o ?g. }

• W2154834417 endingPage "e1003030" @default.
• W2154834417 startingPage "e1003030" @default.
• W2154834417 abstract "Ribonucleoside analogues have potential utility as anti-viral, -parasitic, -bacterial and -cancer agents. However, their clinical applications have been limited by off target effects. Development of antiviral ribonucleosides for treatment of hepatitis C virus (HCV) infection has been hampered by appearance of toxicity during clinical trials that evaded detection during preclinical studies. It is well established that the human mitochondrial DNA polymerase is an off target for deoxyribonucleoside reverse transcriptase inhibitors. Here we test the hypothesis that triphosphorylated metabolites of therapeutic ribonucleoside analogues are substrates for cellular RNA polymerases. We have used ribonucleoside analogues with activity against HCV as model compounds for therapeutic ribonucleosides. We have included ribonucleoside analogues containing 2′-C-methyl, 4′-methyl and 4′-azido substituents that are non-obligate chain terminators of the HCV RNA polymerase. We show that all of the anti-HCV ribonucleoside analogues are substrates for human mitochondrial RNA polymerase (POLRMT) and eukaryotic core RNA polymerase II (Pol II) in vitro. Unexpectedly, analogues containing 2′-C-methyl, 4′-methyl and 4′-azido substituents were inhibitors of POLRMT and Pol II. Importantly, the proofreading activity of TFIIS was capable of excising these analogues from Pol II transcripts. Evaluation of transcription in cells confirmed sensitivity of POLRMT to antiviral ribonucleosides, while Pol II remained predominantly refractory. We introduce a parameter termed the mitovir (mitochondrial dysfunction caused by antiviral ribonucleoside) score that can be readily obtained during preclinical studies that quantifies the mitochondrial toxicity potential of compounds. We suggest the possibility that patients exhibiting adverse effects during clinical trials may be more susceptible to damage by nucleoside analogs because of defects in mitochondrial or nuclear transcription. The paradigm reported here should facilitate development of ribonucleosides with a lower potential for toxicity." @default.
• W2154834417 created "2016-06-24" @default.
• W2154834417 creator A5004285502 @default.
• W2154834417 creator A5011497814 @default.
• W2154834417 creator A5012860564 @default.
• W2154834417 creator A5018583879 @default.
• W2154834417 creator A5019519252 @default.
• W2154834417 creator A5021526153 @default.
• W2154834417 creator A5028461067 @default.
• W2154834417 creator A5035169875 @default.
• W2154834417 creator A5037188019 @default.
• W2154834417 creator A5040465204 @default.
• W2154834417 creator A5042486375 @default.
• W2154834417 creator A5046798175 @default.
• W2154834417 creator A5050848489 @default.
• W2154834417 creator A5062626495 @default.
• W2154834417 creator A5063693441 @default.
• W2154834417 creator A5068133635 @default.
• W2154834417 creator A5082623889 @default.
• W2154834417 creator A5086553695 @default.
• W2154834417 creator A5091665087 @default.
• W2154834417 date "2012-11-15" @default.
• W2154834417 modified "2023-10-06" @default.
• W2154834417 title "Sensitivity of Mitochondrial Transcription and Resistance of RNA Polymerase II Dependent Nuclear Transcription to Antiviral Ribonucleosides" @default.
• W2154834417 cites W1939121468 @default.
• W2154834417 cites W1963623224 @default.
• W2154834417 cites W1966559184 @default.
• W2154834417 cites W1977078068 @default.
• W2154834417 cites W1977139658 @default.
• W2154834417 cites W1987911801 @default.
• W2154834417 cites W2004617021 @default.
• W2154834417 cites W2005655629 @default.
• W2154834417 cites W2007323926 @default.
• W2154834417 cites W2010994647 @default.
• W2154834417 cites W2022029462 @default.
• W2154834417 cites W2023572990 @default.
• W2154834417 cites W2026065136 @default.
• W2154834417 cites W2029766561 @default.
• W2154834417 cites W2032417358 @default.
• W2154834417 cites W2049275544 @default.
• W2154834417 cites W2060495746 @default.
• W2154834417 cites W2069094439 @default.
• W2154834417 cites W2072096008 @default.
• W2154834417 cites W2072855608 @default.
• W2154834417 cites W2076304130 @default.
• W2154834417 cites W2077064549 @default.
• W2154834417 cites W2077565827 @default.
• W2154834417 cites W2085718640 @default.
• W2154834417 cites W2092869716 @default.
• W2154834417 cites W2105754268 @default.
• W2154834417 cites W2106196384 @default.
• W2154834417 cites W2117640369 @default.
• W2154834417 cites W2120004160 @default.
• W2154834417 cites W2120302736 @default.
• W2154834417 cites W2121638813 @default.
• W2154834417 cites W2125096046 @default.
• W2154834417 cites W2126409180 @default.
• W2154834417 cites W2129968561 @default.
• W2154834417 cites W2136647574 @default.
• W2154834417 cites W2147885904 @default.
• W2154834417 cites W2151338378 @default.
• W2154834417 cites W2152721728 @default.
• W2154834417 cites W2162024492 @default.
• W2154834417 cites W2162401151 @default.
• W2154834417 cites W2163818375 @default.
• W2154834417 cites W2163976366 @default.
• W2154834417 cites W2165591669 @default.
• W2154834417 cites W2168586962 @default.
• W2154834417 cites W2171178957 @default.
• W2154834417 cites W2327070670 @default.
• W2154834417 cites W4210438407 @default.
• W2154834417 doi "https://doi.org/10.1371/journal.ppat.1003030" @default.
• W2154834417 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3499576" @default.
• W2154834417 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23166498" @default.
• W2154834417 hasPublicationYear "2012" @default.
• W2154834417 type Work @default.
• W2154834417 sameAs 2154834417 @default.
• W2154834417 citedByCount "119" @default.
• W2154834417 countsByYear W21548344172013 @default.
• W2154834417 countsByYear W21548344172014 @default.
• W2154834417 countsByYear W21548344172015 @default.
• W2154834417 countsByYear W21548344172016 @default.
• W2154834417 countsByYear W21548344172017 @default.
• W2154834417 countsByYear W21548344172018 @default.
• W2154834417 countsByYear W21548344172019 @default.
• W2154834417 countsByYear W21548344172020 @default.
• W2154834417 countsByYear W21548344172021 @default.
• W2154834417 countsByYear W21548344172022 @default.
• W2154834417 countsByYear W21548344172023 @default.
• W2154834417 crossrefType "journal-article" @default.
• W2154834417 hasAuthorship W2154834417A5004285502 @default.
• W2154834417 hasAuthorship W2154834417A5011497814 @default.
• W2154834417 hasAuthorship W2154834417A5012860564 @default.
• W2154834417 hasAuthorship W2154834417A5018583879 @default.
• W2154834417 hasAuthorship W2154834417A5019519252 @default.
• W2154834417 hasAuthorship W2154834417A5021526153 @default.
• W2154834417 hasAuthorship W2154834417A5028461067 @default.
• W2154834417 hasAuthorship W2154834417A5035169875 @default.

• next